Bivalent Degrader Landscape

Although still in their infancy years and largely preclinical, bivalent degraders are continuing their transition to becoming a promising therapeutic area. With an astounding 137% increase in bivalent degrader assets being tracked within the last year, this rapid expansion underscores the immense potential for developers.

To help address this growing landscape, our expert team provided a walk through of all the major shifts in the landscape.